Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of teniposide in anti-mycobacterium tuberculosis drugs

A technology of mycobacterium tuberculosis and teniposide, which is applied in the field of bioengineering, can solve the problems that tuberculosis drugs cannot meet the requirements of patients and tuberculosis prevention and control, and achieve the effects of increasing reuse value, shortening the course of treatment, and reducing development costs

Active Publication Date: 2022-05-03
SHENZHEN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis infection. Current tuberculosis treatment drugs cannot meet the requirements of patients and tuberculosis prevention and control
Due to the occurrence of tuberculosis drug resistance, especially the emergence of multi-drug resistance and extensive drug resistance, tuberculosis control is facing severe challenges

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of teniposide in anti-mycobacterium tuberculosis drugs
  • Application of teniposide in anti-mycobacterium tuberculosis drugs
  • Application of teniposide in anti-mycobacterium tuberculosis drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] In vitro bactericidal activity assay

[0025] 1. Preparation of drugs with different concentrations

[0026] Under sterile conditions, use DMSO to prepare teniposide into a solution with a concentration of 10uM. After fully dissolving, use DMSO to dilute the solution into eight concentration gradients, so that the drug concentrations are: 1uM, 500uM, 250uM, 125uM , 62.5uM, 31.25uM, 15.6uM, 7.8uM are stored at -80℃ for later use;

[0027] 2. Preparation of Mycobacterium tuberculosis (Mtb)

[0028] Culture Mycobacterium tuberculosis H37Rv (No. ATCC27294) in 7H9-OADC medium, dilute Mtb in the logarithmic growth phase (OD600=0.6~0.8) to OD600=0.01, spread 99uL / well on a 96-well cell culture plate middle;

[0029] Add 1ul of the drug with the above concentration gradient to the cultured bacteria, so that the final concentration of the drug is: 10uM, 5uM, 2.5uM, 1.25uM, 625uM, 312uM, 156uM, 78uM, and add 1ul of DMSO to the above eight groups of solutions with the same conc...

Embodiment 2

[0037] 1. Differentiation of U937 macrophages (No. BNCC100967): Suspended U937 macrophages were cultured in RPMI-1640 medium containing 10% FBS, and placed at a temperature of 37°C, containing 5% CO 2 Cultured in a cell incubator, added PMA with a final concentration of 20ng / ml, cultured overnight, differentiated into macrophages, washed twice with PBS, digested with trypsin, resuspended, added to a 96-well cell culture plate , so that the number of cells per well is 1x104;

[0038] 2. Determination of cell survival rate: After culturing the above-mentioned U937 macrophages for 24 hours, add different concentrations of drugs to make the final drug concentrations 10uM, 5uM, and 2.5uM. The experiment was repeated three times for each concentration, and DMSO was used as a parallel control In the experiment, DMSO with the same volume as the drug was added to the control group, and the experiment was repeated three times. After 48 hours, 10ul WST-1 solution was added to each well, ...

Embodiment 3

[0045] 1. Differentiation of U937 macrophages: Suspended U937 macrophages were cultured in RPMI-1640 medium containing 10% FBS, and placed at a temperature of 37°C, containing 5% CO 2 Cultured in a cell incubator, added PMA with a final concentration of 20ng / ml, cultured overnight, differentiated into macrophages, washed twice with PBS, digested with trypsin, resuspended, added to a 96-well cell culture plate , so that the number of cells per well is 1x104;

[0046] 2. Determination of intracellular bactericidal activity: After the above-mentioned U937 macrophages were cultured for 24 hours, teniposide was added to make the final concentration 5uM, and the experiment was repeated three times for each concentration. DMSO was used as a parallel control experiment, and teniposide was added to the control group. DMSO with the same volume as the drug was repeated 3 times. After 4 hours, the medium was sucked off, washed twice with PBS, fresh medium was added for 72 hours, and the l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of teniposide in anti-tuberculosis mycobacterium drugs. Teniposide is mainly used in the treatment of malignant lymphoma and acute lymphoblastic leukemia clinically; and the present invention has found that it has an anti-tuberculosis effect and has good development value; the teniposide involved in the present invention is effective in anti-tuberculosis The application in mycobacterium medicine and teniposide's obvious anti-tuberculosis mycobacterium effect are disclosed for the first time.

Description

technical field [0001] The invention relates to the technical field of bioengineering, in particular to the application of teniposide in anti-tuberculosis mycobacterium drugs. Background technique [0002] Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis infection. The current treatment drugs for tuberculosis cannot meet the requirements of patients and tuberculosis prevention and control. Due to the occurrence of tuberculosis drug resistance, especially the emergence of multi-drug resistance and extensive drug resistance, tuberculosis control is facing severe challenges. According to statistics, among the tuberculosis patients in my country, the incidence rate of multi-drug resistance is 8.32%, totaling about 120,000 people, the total number is second only to India, and the incidence rate of extensive drug resistance is 0.68%, totaling about For 10,000 people, its harm is far more than AIDS. Therefore, the control of tuberculosis urgently r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P31/06
CPCA61K31/7048A61P31/06
Inventor 蔡毅陈心春欧阳琪
Owner SHENZHEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com